• Genentech Acquires Jecure Therapeutics americanpharmaceuticalreview
    November 29, 2018
    Jecure Therapeutics announced a definitive agreement by which it will be acquired by Genentech, a member of the Roche Group. With this acquisition, Genentech will obtain full rights to Jecure’s entire preclinical portfolio of NLRP3 inhibitors......
PharmaSources Customer Service